Moderna says first participants have been dosed in the company’s Phase 2 study of its covid-19 vaccine candidate.
- Phase 2 expected to enroll 600 participants
- Company is finalizing protocol for Phase 3 study, which is expected to begin in July
To view the source of this information click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2020 Bloomberg L.P. All rights reserved. Used with permission.